Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$19.86M+17.5%-$33.76M-69.0%-$26.93M-53.5%-$26.73M-47.5%-$24.06M-6.1%
$227K-7.0%$265K+1.9%$256K+16.9%$252K+21.2%$244K+60.5%
$6.96M+72.4%$5.69M+77.4%$4.74M+48.8%$4.39M+86.4%$4.04M+171%
-$13.06M+35.5%-$24.7M-71.0%-$17.47M-6.4%-$25.07M-53.3%-$20.24M-14.9%
$86K-70.4%$169K-25.2%$134K-4.3%$22K-97.7%$291K-72.9%
$37.94M+80.4%-$174.32M-$56.78M-7.0%$22.6M+121%$21.03M+150%
$531K+10,520%$311K+4,343%$270.53M-$63K-100%$5K-100.0%
$25.41M+3,080%-$198.71M$196.29M+377%-$2.54M-107%$799K-80.6%
-$13.15M+36.0%-$24.87M-69.5%-$17.6M-6.3%-$25.09M-44.9%-$20.53M-9.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Rapport Therapeutics, Inc. generate?
Rapport Therapeutics, Inc. (RAPP) generated -$80.3M in operating cash flow over the trailing twelve months.
What is Rapport Therapeutics, Inc.'s free cash flow?
After $411.0K of capital expenditures, Rapport Therapeutics, Inc.'s free cash flow was -$80.7M over the trailing twelve months, down 16.8% year over year.
Where does Rapport Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.